Electro-Optical Sciences to Commemorate Melanoma Monday at NASDAQ Stock Market

Company to Ring the Opening Bell Monday, May 4th

IRVINGTON, NY--(Marketwire - April 30, 2009) - Electro-Optical Sciences (NASDAQ: MELA) today announced that the company will ring the NASDAQ Stock Market Opening Bell on Monday, May 4, 2009 at 9:30 a.m. EDT, to commemorate Melanoma Monday and the start of National Melanoma/Skin Cancer Detection and Prevention Month®.

"In the midst of our intense activities centered on the completion of our PMA submission for MelaFind, we're reminded of the importance of our efforts as we commemorate Melanoma Monday," said Chief Executive Joseph V. Gulfo, M.D. "Melanoma rates continue to climb at a frightening pace, especially in young women, so it's more vital than ever that we find a reliable way to detect the disease while it is still in its earliest, most curable stages. With MelaFind, we believe we're doing our part to make that goal a reality. We extend our deep appreciation to NASDAQ for recognizing the importance of skin cancer awareness."

In February, EOS announced positive top-line results of its MelaFind pivotal study, the largest prospective study ever conducted in melanoma detection. The company remains focused on completing its MelaFind Pre-Market Approval (PMA) application, which it expects to submit to the U.S. Food and Drug Administration shortly. The results of the pivotal study, as well as a significant body of data from separate trials, will form the basis of the company's PMA filing.

To view the Opening Bell Ceremony online, visit http://www.nasdaq.com/about/marketsitetowervideo.asx

The MarketSite Live Web Cam is located at the bottom of the web page. Please allow sufficient time to download the web cam and install Windows Media Player, if necessary. The live feed will begin at approximately 9:15 a.m. EDT.

Melanoma/Skin Cancer Detection and Prevention Month® is a trademark of the American Academy of Dermatology.

About Electro-Optical Sciences

EOS is a medical device company focused on designing and developing MelaFind®, a non-invasive, point-of-care instrument to assist in the early detection of melanoma. MelaFind features a hand-held imaging device that emits light of multiple wavelengths to capture images of suspicious pigmented skin lesions and extract data. Using sophisticated algorithms, the data are then analyzed against a proprietary database of melanomas and benign lesions in order to provide the clinician with clear and objective information.

Melanoma is the deadliest of skin cancers, responsible for approximately 80% of all skin cancer deaths. Unless melanoma is detected early and excised with proper margins, the patient survival rate is poor, as there is currently no cure for advanced stage melanoma.

For more information visit www.eosciences.com.

Contact Information: For further information contact: Investors: David Carey Lazar Partners Ltd. 212-867-1768 Media: Hollister Hovey Lazar Partners Ltd. 646-871-8482